<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841761</url>
  </required_header>
  <id_info>
    <org_study_id>AC-080-103</org_study_id>
    <nct_id>NCT02841761</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects</brief_title>
  <official_title>A Single-center, Open-label, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxy Midazolam in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of ACT-132577 on the pharmacokinetics of
      midazolam and 1-hydroxy midazolam and to evaluate the safety and tolerability of ACT-132577
      when administered alone and in combination with midazolam.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1, 2016</start_date>
  <completion_date type="Actual">October 1, 2016</completion_date>
  <primary_completion_date type="Actual">September 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plama concentration (Cmax)</measure>
    <time_frame>Midazolam PK sampling on Days 1, 2, 6 and 7</time_frame>
    <description>Cmax of midazolam and 1-hydroxy midazolam following administration of midazolam alone and in combination with ACT-132577</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)</measure>
    <time_frame>Midazolam PK sampling on Days 1, 2, 6 and 7</time_frame>
    <description>AUC0-∞ of midazolam and 1-hydroxy midazolam following administration of midazolam alone and in combination with ACT-132577</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax)</measure>
    <time_frame>Midazolam PK sampling on Days 1, 2, 6 and 7</time_frame>
    <description>Tmax of midazolam and 1-hydroxy midazolam following administration of midazolam alone and in combination with ACT-132577</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Midazolam PK sampling on Days 1, 2, 6 and 7</time_frame>
    <description>T1/2 of midazolam and 1-hydroxy midazolam following administration of midazolam alone and in combination with ACT-132577</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>From Day 1 to Follow-up (for up to 38 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serious adverse events</measure>
    <time_frame>From Screening to Follow-up (for up to 59 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A (Midazolam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Midazolam 8 mg on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B1 (ACT-132577)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of ACT-132577 150 mg on Day 2; single dose of ACT-132577 50 mg on Day 3, Day 4, and Day 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B2 (Midazolam + ACT-132577)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Midazolam 8 mg and single dose of ACT-132577 50 mg on Day 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midalozam</intervention_name>
    <description>Syrup for oral use</description>
    <arm_group_label>Treatment B2 (Midazolam + ACT-132577)</arm_group_label>
    <arm_group_label>Treatment A (Midazolam)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-132577</intervention_name>
    <description>Capsules for oral use</description>
    <arm_group_label>Treatment B1 (ACT-132577)</arm_group_label>
    <arm_group_label>Treatment B2 (Midazolam + ACT-132577)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in the local language prior to any study-mandated procedure

          -  Body mass index (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at screening

          -  Healthy on the basis of medical history, physical examination, cardiovascular
             assessments and serology and laboratory tests

        Exclusion Criteria:

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

